PGD2
metabolitePGD2 is an anti-platelet prostanoid whose post-PCI reduction indicates resolution of acute thrombus-associated inflammation.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleEicosanoid; anti-platelet prostanoid downregulated post-PCI in STEMI, reflecting resolution of platelet-inflammatory phase.
Also acts inThromboxane / COX-1
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I53
C — confounder / Type-II63
A — assay feasibility42
E — evidence strength25
T1DI (composite)5
Specificity differential (R−C)-9.5
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Metabolomics reveal dynamic changes in eicosanoid profile in patients with ST-elevation myocardial infarction after percutaneous coronary intervention.Clinical and experimental pharmacology & physiology · 2021 · PMID 33141433 · doi
Clinical trials(1)
- Biosynthesis of PGD2 in Vascular InjuryNCT01001260 · TERMINATED · No ASA, Low dose ASA, 325 mg ASA